PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-35.35%
Cash & equivalents declining -35.35% while AVXL's grows 4.41%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-35.35%
Below half of AVXL's 4.41%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.32%
Higher Other Current Assets Growth compared to AVXL's zero value, indicating worse performance.
-30.67%
Below half of AVXL's 16.10%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-13.90%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Less than half of AVXL's -100.00%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-10.42%
Below half of AVXL's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Below half of AVXL's 15.30%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-10.38%
50-75% of AVXL's -18.75%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
1404.09%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
10.38%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-3.56%
Less than half of AVXL's 16.21%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.88%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-5.58%
Less than half of AVXL's 16.21%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
1.25-1.5x AVXL's -1.56%. Bruce Berkowitz notes stronger reinvestment strategy.
-5.49%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-43.19%
Below half AVXL's 15.08%. Michael Burry sees potential underperformance in building shareholder capital.
-28.48%
Below half AVXL's 15.30%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
14.13%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
40.09%
Less than half of AVXL's -4.41%. David Dodd sees better deleveraging or stronger cash buildup than competitor.